Clinical Trial Phase I “Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects” completed.

Archived

December 2020 –

tiakis Biotech AG (formerly Proteo Biotech AG) has attained another milestone in its Pulmonary Arterial Hypertension (PAH) development program by receiving the final clinical phase 1 trial report demonstrating the very good safety profile of Tiprelestat (no severe adverse occurred). 

tiakis’s research partners and investigators at Stanford University School of Medicine, Dr. Marlene Rabinovitch and Dr. Roham Zamanian, were responsible for the conduct of the investigator-initiated trial. 

The trial marks the beginning of the clinical development program of Tiprelestat for chronic use focusing on the treatment of patients suffering from the still fatal disease PAH and highlights our commitment to bringing Tiprelestat from bench to bedside.

Contact

tiakis BIOTECH AG
Sophienblatt 40
24103 Kiel
Germany
phone: +49 431 8888-462
fax: +49 431 8888-463
email: info@tiakis.bio